Last Updated on August 26, 2021 by The Health Master
Following the Medicines and Healthcare products Regulatory Agency (MHRA) approval earlier this year, Lupin Healthcare has launched Luforbec (beclometasone / formoterol) 100/6 dose pressurised metered dose inhaler (pMDI).
It is available now to patients in the UK, with the potential to offer significant cost savings for the NHS, the company said in a statement.
Luforbec is indicated for the treatment of adult asthma and for the symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 <50 per cent predicted normal).
Lupin is approved to manufacture Luforbec at its sites in Pithampur in India and Coral Springs in the US, added the statement.
For informative videos by The Health Master, click on the below YouTube icon: